News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • Analysts recommend buying PayPal, citing improving monetization, stabilizing P2P and merchant volumes, and clearer path to higher take-rates.
  • Samsara sees revenue per customer expansion after strong results and an upmarket push, prompting a bullish trade on execution and multiple re-rating.
  • A focused short-term long is advised on Tesla ahead of Q3, citing margin delivery prospects and thin short-covering dynamics.
  • TAT Technologies' 27% pullback creates a buying window after Q2 revenue, gross profit, and net income gains.
  • SailPoint is positioned as the identity control plane for AI agents, posting 34% SaaS growth and strong free cash flow.
  • Multiple buy ideas across payments and software suggest increased investor appetite for growth and cyclicals this hour.

Latest Articles

Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States

Greenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States

Greenland Mines Ltd applauds the historic security agreement between the US, Denmark, and Greenland that expands US presence and limits adversaries' military and investment activities in Greenland. The company highlights Greenland's strategic value, particularly its significant rare earth and precious metal mineral assets critical for defense and e…

Buy Baker Hughes Ahead of a Power-Generation & Gas-Turbine Demand Cycle

Buy Baker Hughes Ahead of a Power-Generation & Gas-Turbine Demand Cycle

Baker Hughes (BKR) is a diversified energy-equipment and services play that looks attractively positioned for a mid-term rerating as power-generation demand (gas turbines, conversions, hydrogen-ready solutions) and LNG expansion drive equipment and aftermarket sales. The stock is trading below several short-term moving averages after a pullback, wh…

Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking

Home BancShares, Inc. Announces Recognition in Forbes Top-Performing Banks and Bank Director RankingBanking

Home BancShares, Inc., parent company of Centennial Bank, was recognized by Forbes and Bank Director for its strong performance among mid-size U.S. banks. Forbes ranked HOMB #5 in Mid-Size Banks based on profitability, growth, capital resilience, and asset quality. Bank Director ranked it #9 in the $5-$50 billion asset group and #18 among the top 2…

HNHPF: Betting on Higher-Margin Server Work as Manufacturing Mix Shifts

HNHPF: Betting on Higher-Margin Server Work as Manufacturing Mix Shifts

Hon Hai Precision (HNHPF) is showing technical stability, rising operational focus on complex server manufacturing, and a ramp in short interest that creates a crowded trade. We prefer a tactical long over a 45-trading-day swing: entry $15.80, stop $14.90, target $18.50. This is a medium-risk, event-driven trade that hinges on improving order mix a…

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients

Teva Pharmaceutical Industries Ltd. released new data highlighting key attributes that healthcare providers prioritize when selecting treatments for tardive dyskinesia (TD) in patients aged 55 and older. The study found that providers value low drowsiness risk, demonstrated long-term efficacy, and favorable drug-drug interaction profiles. Teva's AU…

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs

Teva Pharmaceuticals announced new real-world evidence demonstrating that UZEDY® (risperidone) extended-release injectable suspension helps schizophrenia and bipolar I disorder patients maintain longer treatment adherence compared to other long-acting injectables and oral antipsychotics. The studies showed UZEDY reduces emergency department visits,…

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults

Teva Pharmaceutical Industries Ltd. announced positive post hoc data from its Phase 3 SOLARIS trial evaluating TEV-'749, a once-monthly subcutaneous long-acting injectable formulation of olanzapine for the treatment of adults with schizophrenia. The data demonstrate high rates of patient stabilization, low relapse rates, and sustained remission ove…

Enact Receives Ratings Upgrade from AM Best

Enact Receives Ratings Upgrade from AM Best

Enact Holdings, Inc., a leading U.S. private mortgage insurance provider, announced that AM Best upgraded its insurance financial strength rating from A- to A and elevated its long-term issuer rating from bbb- to bbb, with a stable outlook. This marks Enact's first rating upgrade since coverage began in 2023, reflecting its consistent execution and…

XCharge Reports First Half 2026 Unaudited Financial Results

XCharge Reports First Half 2026 Unaudited Financial Results

XCHG Limited (Nasdaq: XCH), a global provider of high-power EV charging solutions, released its unaudited financial results for the first half of 2026. Revenues decreased by 17.5% to $10.3 million due to customer procurement timing and project schedule changes, resulting in an operating loss of $11.2 million. The company launched new products, esta…

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Amneal Announces FDA Approval and Launch of Lanreotide Injection

Amneal Pharmaceuticals announced FDA approval and immediate launch of its lanreotide injection, a long-acting oncology treatment for acromegaly, GEP-NETs, and carcinoid syndrome. The product has Competitive Generic Therapy designation and is expected to drive growth by expanding Amneal's complex injectables portfolio supported by in-house manufactu…

Radcom Pullback = Opportunity: Trim the Rating, Buy the Setup

Radcom Pullback = Opportunity: Trim the Rating, Buy the Setup

Radcom (RDCM) reported multi-year revenue growth and a net cash-rich balance sheet, yet the stock has pulled back from earlier 2026 highs. We downgrade the rating to reflect heightened near-term execution risk, but we present a mid-term long trade for disciplined buyers who want exposure to telecom network intelligence at an attractive implied valu…

Tesla: FSD, Robotaxis and Solar - A 180-Day Trade Idea

Tesla: FSD, Robotaxis and Solar - A 180-Day Trade Idea

Tesla is priced for perfection today, yet recent policy wins and industrial moves - including a large Texas solar tax break and growing export economics from Shanghai - make a 180-day trade that plays for FSD/robotaxi progress and improving energy economics compelling. This trade idea lays out an entry, stop and target with explicit horizon and ris…

Broadcom Pullback: Tactical Long with a Clear Risk-Reward

Broadcom Pullback: Tactical Long with a Clear Risk-Reward

Broadcom (AVGO) just put a clearer entry on the table after a recent pullback into the low $350s. The company sits squarely at the center of AI infrastructure demand and still throws off large free cash flow, but the shares trade at a premium. This trade idea proposes a disciplined long with a $358.05 entry, $420 target and $335 stop — sized for a …